Clinical Trials on Skin Condition in Russian Federation

Total 6291 results

Bayer
Janssen Research & Development, LLC; Colorado Prevention Center

Completed

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities (VOYAGER PAD)

Peripheral Artery Disease

Poland, Belgium, France, Spain, China, Korea, Republic of, United States, Switzerland, Estonia, Portugal, Japan, Hungary, Canada, Netherlands, Finland, Austria, United Kingdom, Germany, Czechia, Thailand, Brazil, Denmark, Italy, Russian... and more
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Completed

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

Prevention & Control

Belgium, Finland, France, China, United States, Colombia, Ireland, Philippines, Japan, Hungary, Canada, Germany, Australia, Chile, Czechia, Korea, Republic of, Malaysia, Brazil, Denmark, Israel, Russian Federation, South Africa, Ecu... and more
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Sexual Dysfunction | Prostate Cancer

United States, Canada
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED)

Heart Failure | Chronic Kidney Diseases | Type 2 Diabetes Mellitus

Estonia, Belgium, Sweden, Italy, China, United States, Canada, Bulgaria, Chile, Denmark, Hungary, Latvia, Mexico, Russian Federation, Serbia, Spain, Portugal, Romania, Turkey, Poland, Lithuania, Argentina, Australia, Brazil, Czechia, France, Georg... and more
GlaxoSmithKline
Duke Clinical Research Institute

Completed

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States, Argentina, Germany, Poland, Russian Federation, Spain, Taiwan, Czechia, Hungary, Italy, Ukraine, Belgium, Netherlands, South Africa, Sweden, Thailand, Korea, Republic of, Mexico, Bulgaria, Hong Kong, Peru, Philippines, Gree... and more
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Terminated

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) (NAVIGATE ESUS)

Stroke

Denmark, France, Spain, China, United States, Switzerland, Germany, Greece, Korea, Republic of, Portugal, Japan, Israel, Canada, Australia, Turkey, Russian Federation, Sweden, Austria, Czechia, Poland, United Kingdom, Belgium, Brazil, Hungar... and more
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
AbbVie

Active, not recruiting

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, New... and more
AbbVie

Completed

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies (U-EXCEL)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
AbbVie

Completed

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
AbbVie

Active, not recruiting

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
GlaxoSmithKline

Terminated

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

United States, Australia, Canada, Netherlands, Finland, Taiwan, Czechia, Estonia, Spain, Argentina, Belgium, France, Sweden, Germany, Israel, Italy, Korea, Republic of, Singapore, Ukraine, United Kingdom, Austria, Ireland, Thailand, C... and more
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
Boehringer Ingelheim

Completed

GLORIA-AF Registry Program - Second and Third Phases

Stroke | Atrial Fibrillation

Korea, Republic of, United States, Canada, Lebanon, Taiwan, Singapore, China, Japan, Colombia, Mexico, Argentina, Brazil, Russian Federation, Hong Kong, United Arab Emirates, Peru, South Africa, Chile, Ecuador, Saudi Arabia, Ven...
Boehringer Ingelheim
Bayer; GlaxoSmithKline

Completed

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Stroke

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Denmark, El Salvador, Finland, France, Germany, Greece, Hong Kong, India, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, No... and more
Eli Lilly and Company

Active, not recruiting

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Ulcerative Colitis

Spain, United States, China, Australia, Austria, Belgium, France, Italy, United Kingdom, Japan, Hungary, India, Serbia, Taiwan, Russian Federation, Canada, Korea, Republic of, Switzerland, Argentina, Israel, Latvia, Poland, Ukraine, D... and more
Boehringer Ingelheim
Eli Lilly and Company

Completed

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Taiwan, Philippines, Australia, Hong Kong, Korea, Republic of, Canada, Italy, Malaysia, United Kingdom, Mexico, Greece, Spain, Netherlands, Switzerland, Israel, Portugal, Germany, Finland, Norway, Romania, Sweden, Serbia and more
AbbVie

Active, not recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) (U-ACHIEVE)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic... and more
DalCor Pharmaceuticals
Medpace, Inc.; The Montreal Health Innovations Coordinating Center (MHICC); Roche...

Completed

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE)

Acute Coronary Syndrome

Sweden, United States, Brazil, Bulgaria, France, Italy, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Hungary, Poland, Romania, Canada, Argentina, Australia, Austria, Belgium, Chile, Czechia, Denmark, Finland, Isra... and more
AstraZeneca

Terminated

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

Elevated High-sensitivity C-Reactive Protein (hsCRP)

United States, Brazil, Bulgaria, Poland, Russian Federation, South Africa, United Kingdom, Germany, Estonia, Romania, Denmark, Netherlands, Norway, Canada, Mexico, Belgium, Israel, Puerto Rico, Colombia, Argentina, Venezuela, Panama, Urugu... and more
AstraZeneca

Terminated

G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)

Type 2 Diabetes

United States, Brazil, Czech Republic, France, Italy, Korea, Republic of, Poland, Russian Federation, South Africa, Spain, United Kingdom, Vietnam, Germany, Philippines, Malaysia, Sweden, Estonia, Latvia, Lithuania, Finland, Norway and more
Amgen

Completed

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Heart Failure | Cardiovascular Disease | Anemia | Ventricular Dysfunction | Congestive Heart Failure

United States, France, Germany, Italy, Netherlands, Spain, United Kingdom, Belgium, Czechia, Denmark, Hungary, Canada, Australia, Hong Kong, South Africa, Chile, Austria, Puerto Rico, Slovakia, Argentina, Israel, Russian Federation, Polan... and more
Sanofi

Completed

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA)

Acute Coronary Syndrome

Belgium, China, Japan, Denmark, United States, Belarus, Mexico, Philippines, Israel, Austria, Serbia, Estonia, Lithuania, Chile, Colombia, Germany, Latvia, Peru, Ukraine, Egypt, Italy, France, Brazil, India, Guatemala, South Africa, Taiwan, C... and more
AbbVie

Active, not recruiting

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)

Chronic Heart Failure With Reduced Ejection Fraction

China, United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Malaysia, Mexico, New Zealand, Peru and more
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea,... and more
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-1)

Crohn's Disease

China, United States, Spain, Australia, Austria, Belgium, India, Japan, Korea, Republic of, Israel, Russian Federation, Canada, Hungary, Poland, Italy, Turkey, Switzerland, Germany, Brazil, Argentina, Latvia, Romania, Slovakia, Ukraine, Denmar... and more
Janssen Research & Development, LLC
Bayer

Completed

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF)

Coronary Artery Disease | Heart Failure

United States, France, Poland, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Mexico, Portugal, Bulgaria, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic of, Japan, Canada, Netherlands, Den... and more
Bristol-Myers Squibb
Pfizer; Duke Clinical Research Institute

Completed

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Acute Coronary Syndromes

Australia, Germany, Poland, United States, Spain, Brazil, France, Netherlands, Argentina, Mexico, Russian Federation, Colombia, Austria, Belgium, Czechia, Hungary, Israel, Peru, Switzerland, Korea, Republic of, Canada, Romania, Sweden, Ukrai... and more
AstraZeneca

Completed

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] (SOCRATES)

Acute Ischaemic Stroke | Transient Ischaemic Attack

Sweden, United States, Australia, Brazil, Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, Vietnam, Germany, Philippines, China, Hungary, Romania, Ukraine, Hong Kong, Argentina, Bel... and more
GlaxoSmithKline

Completed

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY)

Atherosclerosis

United States, Argentina, Australia, France, Germany, Netherlands, Taiwan, Bulgaria, Estonia, Poland, Russian Federation, Spain, Belgium, Canada, Peru, Philippines, Sweden, Thailand, Korea, Republic of, Hong Kong, Hungary, Slovakia, Ukrain... and more
Celgene

Recruiting

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, ... and more
Celgene

Recruiting

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Poland, Romani... and more
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)

Diabetes Mellitus, Type 2 | Diabetic Nephropathy

United States, Canada, France, Germany, Poland, Ukraine, United Kingdom, China, Taiwan, Spain, Argentina, Colombia, Mexico, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Japan, Australia, Korea, Republic of, Chile, New Zealand and more
Bayer

Active, not recruiting

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF)

Heart Failure

United States, Spain, Denmark, Korea, Republic of, Taiwan, Australia, Hong Kong, Russian Federation, Israel, Canada, Malaysia, United Kingdom, Latvia, Netherlands, Japan, Brazil, China, Lithuania, Poland, Turkey, Italy, Austria, Bul... and more
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Myocardial Infarction | Myocardial Ischemia | Acute Coronary Syndrome | Unstable Angina

United States, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Argentina, Chile, Colombia, Israel, Mexico, Portugal, Bulgaria, India, Malaysia, Romania, Russian Federation, Serbia, Turkey, Korea, Republic of, ... and more
GlaxoSmithKline

Completed

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk (REDUCE)

Neoplasms, Prostate

United States, Australia, France, Germany, Spain, Bulgaria, Estonia, Italy, Poland, Netherlands, Belgium, United Kingdom, Canada, Denmark, Ukraine, Finland, Latvia, Russian Federation, Greece, Slovenia, Brazil, Mexico, Slovakia, Japan, Puerto... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)

Heart Failure With Preserved Ejection Fraction

China, Germany, United States, Colombia, South Africa, Italy, Austria, Belgium, Croatia, Romania, Taiwan, Japan, Netherlands, Denmark, France, Israel, Spain, Switzerland, Korea, Republic of, Argentina, Canada, United Kingdom, Bulgaria, Gree... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN)

Venous Thromboembolism

Belgium, France, Norway, Spain, China, Taiwan, United States, Switzerland, Colombia, Canada, Estonia, New Zealand, Finland, Italy, Portugal, Japan, Singapore, Germany, Greece, Australia, Sweden, Austria, Chile, Slovakia, United Kingdom, M... and more
Hoffmann-La Roche

Completed

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Diabetes Mellitus Type 2

Australia, France, Spain, Sweden, China, Korea, Republic of, United States, Canada, Germany, Ireland, Mexico, Poland, India, Denmark, Hungary, United Kingdom, New Zealand, Malaysia, Netherlands, Russian Federation, Thailand, Romania, Ita... and more
AstraZeneca
Bristol-Myers Squibb

Completed

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications (SAVOR- TIMI 53)

Type 2 Diabetes Mellitus

Sweden, United States, Australia, Brazil, Czech Republic, Italy, Mexico, Peru, Poland, Russian Federation, South Africa, Spain, United Kingdom, Germany, China, Hungary, Netherlands, Canada, Hong Kong, Argentina, Chile, France, Israel, Puerto Rico and more
Novartis Pharmaceuticals

Active, not recruiting

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Cardiovascular Disease and Lipoprotein(a)

United States, China, Germany, South Africa, Italy, Spain, Belgium, Czechia, Hungary, Japan, Taiwan, Netherlands, Australia, Austria, Canada, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Argentina, Denmark, Greece, Romani... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure (ATMOSPHERE)

Chronic Heart Failure

China, United States, Belgium, Colombia, India, Korea, Republic of, Poland, Romania, Italy, Spain, Austria, Estonia, France, Germany, Japan, Taiwan, Turkey, Netherlands, Sweden, Switzerland, United Kingdom, Thailand, Australia, Ireland, Russian Federation and more
Novartis Pharmaceuticals

Completed

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Cardiovascular Disease and Lipoprotein(a)

China, Germany, United States, Colombia, South Africa, Italy, Spain, Belgium, Egypt, Hungary, Taiwan, Turkey, Japan, Netherlands, Australia, Austria, Canada, Czechia, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Th... and more
AstraZeneca

Completed

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease (EUCLID)

Peripheral Artery Disease

United States, Canada, France, Italy, Netherlands, Spain, United Kingdom, Czechia, Thailand, Russian Federation, Vietnam, Germany, Korea, Republic of, Brazil, Hungary, Mexico, Philippines, Turkey, China, Slovakia, Japan, Bulgaria, R... and more
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

Type 2 Diabetes Mellitus

China, United States, Netherlands, Spain, Australia, Austria, India, Canada, Taiwan, Japan, United Kingdom, Belgium, France, Germany, Mexico, Romania, Italy, Argentina, Brazil, Puerto Rico, Ukraine, Hungary, Czechia, Turkey, Korea, Republic... and more
Eli Lilly and Company
Duke Clinical Research Institute; Daiichi Sankyo Co., Ltd.

Completed

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS)

Acute Coronary Syndrome

Argentina, Brazil, Canada, Italy, China, Puerto Rico, Australia, Romania, Russian Federation, France, Germany, United States, Belgium, Bulgaria, Poland, Ukraine, United Kingdom, Colombia, Hungary, Philippines, Croatia, Denmark, India, Chil... and more
Amgen

Active, not recruiting

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

Coronary Heart Disease (CHD)

Canada, France, United States, Spain, United Kingdom, Korea, Republic of, Netherlands, Austria, Australia, Czechia, Taiwan, Finland, Hungary, Italy, Poland, Greece, Germany, Brazil, Latvia, Denmark, Mexico, Russian Federation, Bulgaria and more

Clinical Trials on Skin Condition in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations